blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2471774

EP2471774 - Piperidinyl derivatives as modulators of chemokine receptor activity [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  30.06.2017
Database last updated on 31.03.2026
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): IS		published on 12.08.2020  [2020/33]
Applicant(s)For all designated states
Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton, NJ 08543 / US
[2016/34]
Former [2012/27]For all designated states
Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton, NJ 08543-4000 / US
Inventor(s)01 / Carter, Percy, H.
c/o Bristol-Myers Squibb Company
Route 206 & Province Line Road
Princeton, NJ 08543 / US
02 / Duncia, John, V.
c/o Bristol-Myers Squibb Company
Route 206 & Province Line Road
Princeton, NJ 08543 / US
03 / Cavallaro, Cullen, L.
c/o Bristol-Myers Squibb Company
Route 206 & Province Line Road
Princeton, NJ 08543 / US
04 / Gardner, Daniel, S.
c/o Bristol-Myers Squibb Company
Route 206 & Province Line Road
Princeton, NJ 08543 / US
05 / Hynes, John
c/o Bristol-Myers Squibb Company
Route 206 & Province Line Road
Princeton, NJ 08543 / US
06 / Liu, Rui-qin
c/o Bristol-Myers Squibb Company
Route 206 & Province Line Road
Princeton, NJ 08543 / US
07 / Santella, Joseph, B.
c/o Bristol-Myers Squibb Company
Route 206 & Province Line Road
Princeton, NJ 08543 / US
08 / Dodd, Dharmpal, S.
c/o Bristol-Myers Squibb Company
Route 206 & Province Line Road
Princeton, NJ 08543 / US
 [2012/27]
Representative(s)Beacham, Annabel Rose
Dehns
St Bride's House
10 Salisbury Square
London EC4Y 8JD / GB
[2016/34]
Former [2012/27]Beacham, Annabel Rose
Dehns St Bride's House 10 Salisbury Square London
EC4Y 8JD / GB
Application number, filing date11188840.025.01.2007
[2012/27]
Priority number, dateUS20060762801P27.01.2006         Original published format: US 762801 P
US2007062587423.01.2007         Original published format: US 625874
[2012/27]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2471774
Date:04.07.2012
Language:EN
[2012/27]
Type: B1 Patent specification 
No.:EP2471774
Date:24.08.2016
Language:EN
[2016/34]
Search report(s)(Supplementary) European search report - dispatched on:EP01.06.2012
ClassificationIPC:C07D211/18, C07D211/38, C07D211/52, C07D211/58, C07D211/70, C07D401/12, C07D401/14, C07D405/12, C07D409/12, C07D413/12, C07D417/12, C07D417/14, C07D487/04, C07D491/10, A61K31/45, A61K31/451, A61K31/4523, A61P29/00, A61P37/00
[2012/27]
CPC:
C07D211/52 (EP,US); C07D211/14 (KR); A61P1/04 (EP);
A61P1/16 (EP); A61P11/00 (EP); A61P11/06 (EP);
A61P13/12 (EP); A61P17/06 (EP); A61P19/00 (EP);
A61P19/02 (EP); A61P19/10 (EP); A61P25/00 (EP);
A61P25/28 (EP); A61P29/00 (EP); A61P31/18 (EP);
A61P35/00 (EP); A61P37/00 (EP); A61P37/02 (EP);
A61P37/06 (EP); A61P37/08 (EP); A61P9/00 (EP);
A61P9/04 (EP); A61P9/10 (EP); C07D211/18 (EP,US);
C07D211/38 (EP,US); C07D211/58 (EP,US); C07D211/70 (EP,US);
C07D401/12 (EP,US); C07D401/14 (EP,US); C07D405/12 (EP,US);
C07D409/12 (EP,US); C07D413/12 (EP,US); C07D417/12 (EP,US);
C07D417/14 (EP,US); C07D471/04 (EP,US); C07D487/04 (EP,US);
C07D491/10 (EP,US); C07D491/107 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2016/34]
Former [2012/27]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:Piperidinylderivate als Modulatoren von Chemokinrezeptoraktivität[2012/27]
English:Piperidinyl derivatives as modulators of chemokine receptor activity[2012/27]
French:Dérivés de pipéridinyle en tant que modulateurs de l'activité de récepteur de chimiokine[2012/27]
Examination procedure04.01.2013Examination requested  [2013/08]
20.02.2013Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
02.05.2013Amendment by applicant (claims and/or description)
30.01.2014Despatch of a communication from the examining division (Time limit: M04)
03.06.2014Reply to a communication from the examining division
18.03.2016Communication of intention to grant the patent
12.07.2016Fee for grant paid
12.07.2016Fee for publishing/printing paid
12.07.2016Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP07763650.4  / EP2049486
Opposition(s)26.05.2017No opposition filed within time limit [2017/31]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
02.05.2013Request for further processing filed
02.05.2013Full payment received (date of receipt of payment)
Request granted
23.05.2013Decision despatched
Fees paidRenewal fee
11.11.2011Renewal fee patent year 03
11.11.2011Renewal fee patent year 04
11.11.2011Renewal fee patent year 05
11.01.2012Renewal fee patent year 06
10.01.2013Renewal fee patent year 07
21.01.2014Renewal fee patent year 08
13.01.2015Renewal fee patent year 09
11.01.2016Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU25.01.2007
AT24.08.2016
BE24.08.2016
CY24.08.2016
CZ24.08.2016
DK24.08.2016
EE24.08.2016
ES24.08.2016
FI24.08.2016
IT24.08.2016
LT24.08.2016
LV24.08.2016
MC24.08.2016
NL24.08.2016
PL24.08.2016
RO24.08.2016
SE24.08.2016
SI24.08.2016
SK24.08.2016
TR24.08.2016
BG24.11.2016
GR25.11.2016
IS24.12.2016
PT26.12.2016
IE25.01.2017
LU25.01.2017
CH31.01.2017
LI31.01.2017
[2020/33]
Former [2020/15]HU25.01.2007
AT24.08.2016
BE24.08.2016
CY24.08.2016
CZ24.08.2016
DK24.08.2016
EE24.08.2016
ES24.08.2016
FI24.08.2016
IT24.08.2016
LT24.08.2016
LV24.08.2016
MC24.08.2016
NL24.08.2016
PL24.08.2016
RO24.08.2016
SE24.08.2016
SI24.08.2016
SK24.08.2016
TR24.08.2016
BG24.11.2016
GR25.11.2016
PT26.12.2016
IE25.01.2017
LU25.01.2017
CH31.01.2017
LI31.01.2017
Former [2019/46]HU25.01.2007
AT24.08.2016
BE24.08.2016
CY24.08.2016
CZ24.08.2016
DK24.08.2016
EE24.08.2016
ES24.08.2016
FI24.08.2016
IT24.08.2016
LT24.08.2016
LV24.08.2016
MC24.08.2016
NL24.08.2016
PL24.08.2016
RO24.08.2016
SE24.08.2016
SI24.08.2016
SK24.08.2016
BG24.11.2016
GR25.11.2016
PT26.12.2016
IE25.01.2017
LU25.01.2017
CH31.01.2017
LI31.01.2017
Former [2019/31]HU25.01.2007
AT24.08.2016
BE24.08.2016
CZ24.08.2016
DK24.08.2016
EE24.08.2016
ES24.08.2016
FI24.08.2016
IT24.08.2016
LT24.08.2016
LV24.08.2016
MC24.08.2016
NL24.08.2016
PL24.08.2016
RO24.08.2016
SE24.08.2016
SI24.08.2016
SK24.08.2016
BG24.11.2016
GR25.11.2016
PT26.12.2016
IE25.01.2017
LU25.01.2017
CH31.01.2017
LI31.01.2017
Former [2018/13]AT24.08.2016
BE24.08.2016
CZ24.08.2016
DK24.08.2016
EE24.08.2016
ES24.08.2016
FI24.08.2016
IT24.08.2016
LT24.08.2016
LV24.08.2016
MC24.08.2016
NL24.08.2016
PL24.08.2016
RO24.08.2016
SE24.08.2016
SI24.08.2016
SK24.08.2016
BG24.11.2016
GR25.11.2016
PT26.12.2016
IE25.01.2017
LU25.01.2017
CH31.01.2017
LI31.01.2017
Former [2017/51]AT24.08.2016
BE24.08.2016
CZ24.08.2016
DK24.08.2016
EE24.08.2016
ES24.08.2016
FI24.08.2016
IT24.08.2016
LT24.08.2016
LV24.08.2016
MC24.08.2016
NL24.08.2016
PL24.08.2016
RO24.08.2016
SE24.08.2016
SI24.08.2016
SK24.08.2016
BG24.11.2016
GR25.11.2016
PT26.12.2016
LU25.01.2017
CH31.01.2017
LI31.01.2017
Former [2017/45]AT24.08.2016
BE24.08.2016
CZ24.08.2016
DK24.08.2016
EE24.08.2016
ES24.08.2016
FI24.08.2016
IT24.08.2016
LT24.08.2016
LV24.08.2016
MC24.08.2016
NL24.08.2016
PL24.08.2016
RO24.08.2016
SE24.08.2016
SI24.08.2016
SK24.08.2016
BG24.11.2016
GR25.11.2016
PT26.12.2016
Former [2017/37]AT24.08.2016
BE24.08.2016
CZ24.08.2016
DK24.08.2016
EE24.08.2016
ES24.08.2016
FI24.08.2016
IT24.08.2016
LT24.08.2016
LV24.08.2016
NL24.08.2016
PL24.08.2016
RO24.08.2016
SE24.08.2016
SI24.08.2016
SK24.08.2016
BG24.11.2016
GR25.11.2016
PT26.12.2016
Former [2017/32]AT24.08.2016
BE24.08.2016
CZ24.08.2016
DK24.08.2016
EE24.08.2016
ES24.08.2016
FI24.08.2016
IT24.08.2016
LT24.08.2016
LV24.08.2016
NL24.08.2016
PL24.08.2016
RO24.08.2016
SE24.08.2016
SK24.08.2016
BG24.11.2016
GR25.11.2016
PT26.12.2016
Former [2017/13]AT24.08.2016
ES24.08.2016
FI24.08.2016
IT24.08.2016
LT24.08.2016
LV24.08.2016
NL24.08.2016
SE24.08.2016
GR25.11.2016
PT26.12.2016
Former [2017/12]AT24.08.2016
ES24.08.2016
FI24.08.2016
IT24.08.2016
LT24.08.2016
NL24.08.2016
SE24.08.2016
GR25.11.2016
PT26.12.2016
Former [2017/10]FI24.08.2016
IT24.08.2016
LT24.08.2016
NL24.08.2016
SE24.08.2016
Former [2017/09]FI24.08.2016
IT24.08.2016
LT24.08.2016
NL24.08.2016
Former [2017/07]LT24.08.2016
Documents cited:Search[I] US6344449  (RUDOLF KLAUS et al.)
 [I] US2004006067  (FOTSCH CHRISTOPHER H et al.)
 [I] US2005227968  (LUSTENBERGER PHILIPP et al.)
 [I] WO02092582  (GRAFFINITY PHARMACEUTICALS AG et al.)
 [I] WO02070511  (BRISTOL MYERS SQUIBB CO et al.)
 [I] US6194448  (BIEDIGER RONALD J et al.)
by applicantWO2005021500
 WO2004043965
 US2004162282
   LUSTER, NEW ENG. J. MED., vol. 338, 1998, pages 436 - 445
   ROLLINS, BLOOD, vol. 90, 1997, pages 909 - 928
   HORUK, TRENDS PHARM. SCI., vol. 15, 1994, pages 159 - 165
   ZLOTNIK, OSHIE, IMMUNITY, vol. 12, 2000, pages 121
   BEN-BARRUCH ET AL., CELL, vol. 72, 1993, pages 415 - 425
   CHARO ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 2752 - 2756
   COMBADIERE ET AL., J. BIOL. CHEM., vol. 270, 1995, pages 16491 - 16494
   POWER ET AL., J. BIOL. CHEM., vol. 270, 1995, pages 19495 - 19500
   SANSON ET AL., BIOCHEMISTRY, vol. 35, 1996, pages 3362 - 3367
   BABA ET AL., J. BIOL. CHEM., vol. 272, 1997, pages 14893 - 14898
   YOSHIE ET AL., J. LEUKOC. BIOL., vol. 62, 1997, pages 634 - 644
   NAPOLITANO ET AL., J. IMMUNOL., vol. 157, 1996, pages 2759 - 2763
   BONINI ET AL., DNA AND CELL BIOL., vol. 16, 1997, pages 1249 - 1256
   SCHWEICKERT ET AL., J. BIOL. CHEM., vol. 275, 2000, pages 90550
   WELLS, SCHWARTZ, CURR. OPIN. BIOTECH., vol. 8, 1997, pages 741 - 748
   P. H. CARTER, CURRENT OPINION IN CHEMICAL BIOLOGY, vol. 6, 2002, pages 510
   TRIVEDI ET AL., ANN. REPORTS MED. CHEM., vol. 35, 2000, pages 191
   SAUNDERS, TARBY, DRUG DISC. TODAY, vol. 4, 1999, pages 80
   PREMACK, SCHALL, NATURE MEDICINE, vol. 2, 1996, pages 1174
   BRUMMET, M. E., J. IMMUN., vol. 164, 2000, pages 3392 - 3401
   COOK, D. ET AL., SCIENCE, vol. 269, 1995, pages 1583 - 1585
   CHINTALACHARUVU, S. R., IMMUN. LETT., 2005, pages 202 - 204
   GAO, B. ET AL., J. EXP. MED., vol. 185, 1997, pages 1959 - 1968
   ALISA KOCH ET AL., J. CLIN. INVEST., vol. 93, 1994, pages 921 - 928
   PEASE, J. E., HORUK, R., EXPERT OPIN. INVEST. DRUGS, vol. 14, 2005, pages 785 - 796
   KARPUS, W. J. ET AL., J. IMMUN., 1995, pages 5003 - 5010
   LUKACS, N. W. ET AL., J. CLIN. INVEST., vol. 95, 1995, pages 2868 - 2876
   CARTER, P. H., CURR. OPIN CHEM. BIO., vol. 6, 2002, pages 510 - 525
   BECK, L. A. ET AL., J. IMMUN., vol. 159, 1997, pages 2962 - 2972
   BARNES, D. A. ET AL., J. CLIN INVEST., vol. 101, 1998, pages 2910 - 2919
   SHAHRARA, S. ET AL., ARTHRITIS & RHEUM., vol. 52, 2005, pages 1907 - 1919
   PLATER-ZYBERK, C. ET AL., IMM. LETT., vol. 57, 1997, pages 117 - 120
   CARSON, K. G. ET AL., ANN. REPORTS MED. CHEM., vol. 39, 2004, pages 149 - 158
   STEVEN D. YOUNG ET AL., ANTIMICROBIAL AGENTS AND CHEMOTHERAPHY, 1995, pages 2602 - 2605
   "Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY, pages: 1418
   CAMILLE G. WERMUTH ET AL.: "The Practice of Medicinal Chemistry", 1996, ACADEMIC PRESS
   "Design of Prodrugs", 1985, ELSEVIER
   "A Textbook of Drug Design and Development", 1991, HARWOOD ACADEMIC PUBLISHERS, pages: 113 - 191
   BERNARD TESTA, JOACHIM M. MAYER: "Hydrolysis in Drug and Prodrug Metabolism", 2003, WILEY-VCH
   GREENE, WUTS: "Protective Groups In Organic Synthesis", 1999, WILEY AND SONS
   SHARPLESS, DEMKO, J. ORG. CHEM., vol. 66, 2001, pages 7945 - 7950
   LIZOTTE, J. ORG. CHEM., vol. 48, no. 20, 1983, pages 3594 - 3597
   SHARPLESS, J. ORG. CHEM., vol. 57, 1992, pages 2768
   CURRY, J. MED. CHEM., vol. 31, 1988, pages 861
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.